cln-081
cullinan oncology,otsuka
['sclc', 'nsclc', 'cln-081 ']
a clinical trial of cln-081 in egfr exon 20 insertion+ nsclc by n=73
orr=38.4% (across all dose levels)
mpfs=10 months prelim evidence of cns activity observed with doses &lt; 150 mg bid, no grade 3 or rash promising option for egfr exon 20 insertion nsclc
#asco22 
Oncologist taking care of people with cancer at Georgetown University | Father/husband/immigrant | #SoMeEditor @ClinicalLung | #LCSM